Fig. 2.6.14 Monorail system follow cannulation of the CCA using a guide catheter or a guide sheath. Then procedure is continued - if necessary and always under protection - with predilatation of the lesion, stent implantation and (also if necessary) postdilatation of the stent. When insertion of a brain protection device is impossible, predilatation of the lesion using a coronary balloon can be done in order to help pass the protection device distally to the lesion. When the procedure is finished, the protection device is withdrawn.
Using a proximal occlusion device as a protection system is quite a different procedure. After inserting the guide catheter into the CCA, an occlusion balloon is inflated in the upper part of the CCA and, according to the type of system, a second occlusion balloon is inflated in the ECA and so reversed blood flow is created. The procedure is then continued with stenting and, if necessary, pre- or post-dilatation is done and the protection system is withdrawn.
188.8.131.52 Step 4: Control Angiography
Intervention is completed with angiographic control of the extra- and intracranial circulation.
Carotid angioplasty and stenting is performed using local anaesthesia under the anaesthetist's care, checking the patient's consciousness, motility and sensitivity levels during the whole procedure. Preoperatively, the patient is given salicylic acid and clopidogrel. During the procedure a bolus administration of 70-100 IU/kg unfrac-tionated heparin is given in order to raise their activated partial prothrombin time to 200-300 s. An intravenous bolus of atropine (0.6-1 mg) is administered before dilatation in order to decrease the risk of major bradycardia due to carotid sinus stimulation when the carotid bulb is dilated. In very rare situations a temporary pacemaker may be needed. During the intervention, monitoring of blood pressure, cardiac pulse, arterial blood oxygen saturation as well as roughly the neurological condition of the patient is essential. When possible a transcranial Doppler ultrasound is performed.
In most cases the procedure is successfully completed with a residual stenosis of <30%. In the early days, the rate of technical failure was up to 10%, but continuous improvement in materials and experience has reduced this rate to less than 2% [59, 60].
This is a rather rare complication involving patient confusion and neurological deficit. It is attributed to blood-brain barrier disturbance and extravasation of contrast agent. A CT scan can reveal signs of oedema and cortical enhancement which, however, soon vanish without leaving permanent neurological deficit .
The most common complication of this kind is haema-toma at the puncture site or in the retroperitoneal area. Rarely, a false aneurysm may develop. There are also reports of common femoral artery dissection, most likely secondary to closure-device misplacement leading to occlusion and needing surgical exploration .
184.108.40.206 Hyperperfusion Syndrome (Fig. 2.6.16)
Brain cells have the ability to autoregulate blood circulation in response to a large range of systematic arterial blood pressure values. The presence of high-grade stenosis in the ICA leads to maximal arterial vasodilatation in order to preserve cerebral perfusion. When stenosis is treated by CAS, blood flow is increased in dilated cerebral vessels. If autoregulation does not respond accordingly, there is the possibility of increased perfusion, oedema or even brain haemorrhage . The patient may suffer from headaches, seizures or even focal neurological symptoms and changes in their level of consciousness. The hyperperfusion occurrence rate ranges from 1.1% to 6.8% and is related to a high death rate (up to 40%) [1, 11]. It is associated with patients who have high-grade stenosis, a significant contralateral lesion and periproce-dural hypertension. Patients should therefore be closely monitored for their ability to maintain systemic arterial blood pressure at the level of 140 mmHg. Transcranial Doppler findings of increased velocities are indicative of the patient's high risk of developing the syndrome and may help in early diagnosis and treatment .
220.127.116.11 Hypotension and Bradycardia
Angioplasty and stenting of plaques located in the carotid bulb may result in haemodynamic alterations due to stimulation of the carotid sinus reflex. Stimulation of barore-ceptors leads to increased parasympathetic discharge and a reduction in the sympathetic discharge, which results in hypotension and bradycardia. Rates vary between 7% and 68% [14, 47]. This complication may develop late after angioplasty (after the first 24 h) and may last for up to 10 days, without however increasing the risk of neurological complications . Treatment initially involves fluid and atropine administration. Persistent hypotension may require the administration of vasoconstriction drugs and rarely a temporary pacemaker [21, 37].
Neurological events due to emboli are one of the most severe and life-threatening complications. Emboli production is possible in nearly all phases of angioplasty. Neurological event rates are decreasing as materials improve and experience grows. The combined 30-day stroke and death rate in various reports range between 4% and 10%. Brain protection systems have improved angioplasty results in such a way that recent reports estimate 30-day combined stroke and death rate at 1.8-3.3% [2, 13, 16, 19, 24, 25, 27, 29, 42, 48].
18.104.22.168 Complications Involving Brain Protection Devices
The use of brain protection devices is now considered almost mandatory in carotid artery angioplasty procedures. However, their use is also linked with certain complications. These complications refer to the introduction and deployment of the devices as well as to tolerance, effectiveness and, most commonly, to device retrieval.
Balloon occlusion devices are not always tolerated and filters can be the cause of spasm and dissection of the artery . Debris may well end up in the brain, being transferred by the collateral circulation of the ECA . Also they may not be captured by the filter device or slip out as the withdrawal catheter is being retrieved [43, 44, 58]. Finally brain protection systems increase the duration, technical difficulty and the cost of the procedure.
Patients who do not suffer from any kind of complication after angioplasty may safely leave hospital on the first or second postoperative day, while in some cases patients can leave hospital in the evening of the day of operation .
It is necessary that patients undergo an examination of their neurological condition at regular periods as well as Duplex ultrasound control for possible asymptomatic restenosis, which in several trials is reported to be 5-20% after 5 years [30, 50, 53]. Complete physical and neurological examination along with Duplex control of the carotid arteries in 6 and 12 months and then yearly is considered a sufficient postoperative follow-up. In cases where Duplex control reveals gradient restenosis, pa
0809007697-16 ' ' M PHtLl'S ISei
tients should be examined more frequently. If restenosis becomes haemo dynamically important and over 70%, a new DSA of the carotid arteries will be necessary in order to verify Duplex findings and determine the need for a possible new angioplasty.
2.6.10 Carotid Angioplasty and Stenting (CAS): Present and Future
Carotid endarterectomy (CEA), having good results for symptomatic and asymptomatic patients [4, 40], was considered the gold standard for carotid occlusive disease. It is therefore for CAS plus brain protection systems to prove that it is at least as effective as endarterectomy.
There are two main questions to be answered:
• Endarterectomy or angioplasty?
• Use brain protection systems or not?
The question of whether to use stents or not with carotid angioplasty does not exist.
The CAVATAS trial  showed equal results regarding major complications (stroke and death) for CAS and CEA, while there was a statistically significant difference in favour of angioplasty regarding lesser complications such as cranial nerve injury or haematomas. The 1-year follow-up showed an increased rate of restenosis for the endovascular treatment but the 3-year follow-up, however, did not reveal any difference in stroke events between the two methods.
The SAPHIRE trial , focusing on mortality as well as stroke and myocardial infarction rates in the 1-year follow-up, showed results such as 12.2% and 20.1% for
CAS and CEA respectively (p=0.004). Reoperation rates in the 1-year follow-up were 0.6% and 4.3% for CAS and CEA, respectively (p=0.04).
The CARESS trial  revealed the same 30-days stroke- and myocardial ischaemia-related mortality rate (2%) for both methods.
Based on these results carotid angioplasty and stent-ing with the use of brain protection systems seem to have equally good results as endarterectomy, and have the additional advantage of being minimally interventional.
Furthermore, materials are being improved and have become less traumatic, more flexible and have a smaller cross-sectional profile. Drug-eluting stents have already given good results in coronary interventions by reducing the restenosis rate, while implementation of biodegradable stents is thought to produce natural remodelling of the vessels [5, 39, 52]. There is also significant progress in the study of plaques, which will enable better patient selection, while progress in drugs research has produced agents capable of reducing stroke rates [23, 46].
Bearing in mind that CAS is a new method, with continuous evolution of materials and technique it seems that the treatment of carotid occlusive disease is entering a new era. Results from new and larger clinical trials will answer our questions. Reports showed that CAS represented 8% of all interventions for carotid stenosis in Europe for the year 2000 . It is estimated that this percentage will grow to 60% by the year 2006.
1. Abou-Chebl A, Yaclar JS, Reginelli JP, Bajzer C, Bhatt D, Krieger DW (2004) Intracranial hemorrhage and hyper-perfusion syndrome following carotid artery stenting: risk factors, prevention and treatment. J Am Coll Cardiol 43:1596-1601
2. Ahmadi R, Willfort A, Lang W, Schillinger M, Alt E, Gschwandtner ME, Haumer M, Maca T, Ehringer H, Minar E (2001) Carotid artery stenting: effect of learning curve and intermediate-term morphological outcome. J Endovasc Ther 8:539-546
3. Al-Mubarak N, Vitek JJ, Lyer S, New G, Leon MB, Roubin GS (2001) Embolization via collateral circulation during carotid stenting with the distal balloon protection system. J Endovasc Ther 8:354-357
4. Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group (MRC) (2004) Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363:1491-1502
5. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ (2004) A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 364:583-591
6. el-Barghouty N, Geroulakos G, Nicolaides A, Androulakis A, Bahal V (1995) Computer assisted carotid plaque characterization. Eur J Vasc Endovasc Surg 9:389-393
7. Becquemin JP (2004) Carotid artery disease: endovascular treatment of carotid disease. In: Hallet JW, Milla JL, Earn-shaw JJ, Reekers JA (eds) Comprehensive vascular and en-dovascular surgery. Mosby, New York
8. Biasi GM, Ferrari SA, Nicolaides AN, Mingazzini PM, Reid D (2001) The ICAROS Registry of Carotid Artery Stenting. J Endovasc Ther 8:46-52
9. CARESS Steering Committee (2003) Carotid revasculariza-tion using endarterectomy or stenting systems (CARESS): phase I clinical trial. J Endovasc Ther 10:1021-1230
10. CAVATAS Investigators (2001) Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Lancet 357:1729-1737
11. Couts SB, Hill MO, Hu WY (2003) Hyperperfusion syndrome: toward a stricter definition. Neurosurgery 53:1053-1058
12. Cremonesi A, Manetti R, Setacci F, Setacci C, Castriota F (2003) Protected carotid stenting clinical advantages and complications of embolic protection devices in 442 consecutive patients. Stroke 34:1936-1943
13. Criado Frank, Lingel Bach JM, Ledesma DF, Lucas PR (2002) Carotid artery stenting in a vascular surgery practice. J Vasc Surg 35:430-434
14. Dangas G, Laird JR Jr, Satler LF, Mehran R, Mintz GS, Lar-rain G, Lansky AJ, Gruberg L, Parsons EM, Laureno R, Monsein LH, Leon MB (2000) Postprocedural hypotension after carotid artery stent placement: predictors and short and long term clinical outcomes. Radiology 215:677-683
15. Dangas G, Monsein LH, Laureno R, Peterson MA, Laird JR Jr, Satler LF, Mehran R, Leon MB (2001) Transient contrast encephalopathy after carotid artery stenting. J Endovasc Ther 8:111-113
16. Diethrich EB, Ndiye M, Reid DB (1996) Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg 3:42-62
17. European Carotid Surgery Trialists Collaborative Group (1998) Randomized trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351:1379-1387
18. Garrido E, Montoya J (1981) Transluminal dilatation of internal carotid artery in fibromuscular dysplasia: a preliminary report. Surg Neurol 16:469-471
19. Golledge J, Mitchell A, Greenhalg RM, Davies AH (2000) Systematic comparison of the early outcome of angioplasty and endarterectomy for symptomatic carotid artery disease. Stroke 31:1439-1443
20. Greenhalgh RM et al (2002) Carotid stenting will become the gold standard: against the motion. In: Greenhalgh RM et al (eds) The evidence for vascular or endovascular reconstruction. Saunders, Philadelphia
21. Harrop JS, Sharan AD, Benitez RP, Armonda R, Thomas J, Rosenwasser RH (2001) Prevention of carotid angioplasty induced bradycardia and hypotension with temporary venous pacemakers. Neurosurgery 49:814-822
22. Hartman M, Weber R, Zouba S, Schranz C, Knauth M (2004) Fatal subarachnoid hemorrhage after carotid stent-ing. J Neuroradiol 31:63-66
23. Heart Protection Study Collaborative Group (2002) MRS / BHF Heart Protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
24. Henry M, Amor M, Henry I, Klonaris C, Chati Z, Masson I, Kownator S, Luizy F, Hugel M (1999) Carotid stenting with cerebral protection: first clinical experience using the Percu Surg Guard Wire System. J Endovasc Surg 6:321-331
25. Henry M, Polydorou A, Henry I, Polydorou A, Hugel M (2004) Carotid angioplasty under cerebral protection with the PercuSurge Guardwire system. Catheter Cardiovasc In-terv 61:293-305
26. Hui C, Baker D, Platts A (2003) The role of percutaneous transluminal angioplasty in the treatment of carotid fibromuscular dysplasia. Eur J Vasc Endovasc Surg Extra 5:102-105
27. Jaeger HJ, Mathias KD, Hauth E, Drescher R, Gissler HM, Hennigs S, Christmann A (2002) Cerebral ischemia detected with diffusion-weighted MR imaging after stent implantation in the carotid artery. Am J Neuroradiol 23:200-207
28. Kachel R (1996) Results of balloon angioplasty in the carotid artery. J Endovasc Surg 3:22-30
29. Kastrup A, Groschel K, Krapf H, Brehm BR, Dichgans J, Schulz JB (2003) Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke 34:813-819
30. Lal B, Hobson R, Goldstein J, Geohagan M, Chakhtoura E, Pappas P, Jamil Z, Haser P, Varma S, Padberg F, Cerveira J (2003) In stent recurrent stenosis after carotid artery stent-ing: life table analysis and clinical relevance J Vasc Surg 38:1162-1167
31. Leisch F, Kerschner K, Hofmann R, Steinwender C, Grund M, Bibl D, Leisch FA Jr, Bergmann H (2003) Carotid sinus reactions during carotid artery stenting: predictors, incidence and influence or clinical outcome. Catheter Cardio-vasc Intervent 58:516-523
32. Mackey W, Naylor R (2004) Carotid artery disease: natural history and diagnosis. In: Hallet JW, Milla JL, Earnshaw JJ, Reekers JA (eds) Comprehensive vascular and endovascular surgery. Mosby, New York
33. Mathias K (1977) Ein neuartiges Katheter-System zur per-cutanen transluminalen Angioplastie von Karotis stenosen. Fortschr Med 95:1007-1011
34. Mathias K, Bockenheimer S, von Reutern G, Heiss HW, Os-thein-Dzerowycz W (1983) Katheter dilatation hirnversorgender Arterien. Der Radiologe 23:208-214
35. Mathias K, Jager H, Hennigs S, Gissler HM (2001) Endo-luminal treatment of internal artery carotid artery stenosis. World J Surg 25:328-326
36. Mathur A, Dorros G, Iyer SS, Vitek JJ, Yadav SS, Roubin GS (1997) Palmaz stent compression in patients following carotid artery stenting. Cathet Cardiovasc Diagn 41:137-140
37. Mlekush W, Schillinger M, Sabeti S, Nachtmann T, Lang W Achmadi R, Minar E (2003) Hypotension and bradycardia after elective carotid stenting: frequency and risk factors. J Endovasc Ther 10:851-859
38. Montauban van Awijndregt A, Elbers HRJ, Moll FL, de Letter J, Ackerstaff RGA (1998) Ultrasonographic characterization of carotid plaques. Ultrasound Med Biol 24:489-493
39. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators (2003) Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323
40. North American Symptomatic Carotid Endarterectomy Trial Collaborators (1998) Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 339:1415-1425
41. Numaguchi Y, Puxau FA, Provenza LJ, Richardson PE (1984) Percutaneous transluminal angioplasty of the carotid artery. Its application to post surgical stenosis. Neuroradiol-ogy 26:527-530
42. Ohki T, Marin ML, Lyon RT, Berdejo GL, Soundararajan K, Ohki M, Yuan JG, Faries PL, Wain RA, Sanchez LA, Suggs WD, Veith FJ (1998) Ex vivo human carotid artery bifurcation stenting: correlation of lesion characteristics with em-bolic potential. J Vasc Surg 27:463-471
43. Ohki T, Roubin GS, Veith FJ, Iyer SS, Brady E (1999) The efficacy of a filter device in preventing embolic events during carotid artery stenting: an ex-vivo analysis. J Vasc Surg 30:1034-1044
44. Ohki T, Veith FJ, Grenell S, Lipsitz EC, Gargiulo N, McKay J, Valladares J, Suggs WD, Kazmi M (2002) Initial experience with cerebral protection devices to prevent embolization during carotid stenting. J Vasc Surg 36:1175-1185
45. Pfefferkorn T, Mayer T, Von Stuckrad-Barre S, Covi M, Hamann GF (2001) Hyperperfusion-induced intracerebral hemorrhage after carotid artery stenting documented by TCD. Neurology 57:1933-1935
46. PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041
47. Qureshi AI, Luft AR, Sharma M, Janardhan V, Lopes DK, Khan J, Guterman LR, Hopkins LN (1999) Frequency and determinants of post procedural hemodynamic instability after carotid angioplasty and stenting. Stroke 30:2086-1093
48. Reimers B, Schluter M, Castriota F, Tubler T, Corvaja N, Cernetti C, Manetti R, Picciolo A, Liistro F, Di Mario C, Cremonesi A, Schofer J, Colombo A (2004) Routine use of cerebral protection during carotid artery stenting: results of a multicenter registry of 753 patients. Am J Med 116:217-222
49. SAPPHIRE Investigators (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) (2004) Protected carotid-artery stenting versus endarterec-tomy in high-risk patients. 351:1493-1501
50. Setacci C, Pula G, Baldi I, de Donato G, Setacci F, Cappelli A, Pieraccini M, Cremonesi A, Castriota F, Neri E (2003) Determinants of in stent restenosis after carotid angioplasty: a case control study. J Endovasc Ther 10:1031-1038
51. Sharma BK, Jain S, Bali HK, Jain A, Kumari S (2000) A follow up study of balloon angioplasty and de novo stenting in Takayasu arteritis. Int J Cardiol 75:147-152
52. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators (2004) A polymer based, paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med 350:221-231
53. Tan K, Cleveland T, Berczi V, McKevitt F, Venables G, Gaines P (2003) Timing and frequency of complications after carotid artery stenting: what is the optimal period of observation? J Vasc Surg 38:236-242
54. Theron J, Cosgrove R, Melanson D, Ethier R (1986) Embo-lization with temporary balloon occlusion of the internal carotid of vertebral arteries. Neuroradiology 28:246-253
55. Theron J, Raymond J, Casasco A, Courtheoux F (1987) Percutaneous angioplasty of atherosclerotic and postsur-gical stenosis of carotid arteries. AJNR Am J Neuroradiol 8:495-500
56. Theron J, Payelle G, Coskum O, Huet H, Guimaraens C (1996) Carotid artery stenosis: treatment with protected balloon angioplasty and stent placement. Radiology 201:627-636
57. Tievsky AL, Droy EM, Mardiat JG (1983) Transluminal angioplasty in postsurgical stenosis of the extracranial carotid artery. Am J Neuroradiol 4:800-802
58. Tubler T, Schluter M, Dirsch O, Sievert H, Bosenberg I, Grube E, Waigand J, Schofer J (2001) Balloon protected carotid artery stenting. Relationship of periprocedural neurological complications with the size of particulate debris. Circulation 104:2791-2796
59. Wholey MH, Wholey M, Mathias K, Roubin GS, Diethrich EB, Henry M, Bailey S, Bergeron P, Dorros G, Eles G, Gaines P, Gomez CR, Gray B, Guimaraens J, Higashida R, Ho DS, Katzen B, Kambara A, Kumar V, Laborde JC, Leon M, Lim M, Londero H, Mesa J, Musacchio A, Myla S, Ramee S, Ro-driquez A, Rosenfield K, Sakai N, Shawl F, Sievert H, Teitel-baum G, Theron JG, Vaclav P, Vozzi C, Yadav JS, Yoshimura SI (2000) Global experience in cervical carotid artery stent placement. Catheter Cardiovasc Interv 50:160-167
60. Wholey MH, Al-Mubarek N, Wholey M (2003) Updated review of the global carotid artery stent registry. Catheter Cardiovasc Interv 60:259-266
Was this article helpful?